Standard BioTools Inc. Increase (Decrease) in Accrued Liabilities
Standard BioTools Inc. (LAB) reported Increase (Decrease) in Accrued Liabilities of -$14.14 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-05
- Standard BioTools Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was $6.64M, a 28.07% decline year-over-year.
- Standard BioTools Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$20.79M.
- Standard BioTools Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was $98.00K.
- Standard BioTools Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was $8.77M.
- Standard BioTools Inc. increase (decrease) in accrued liabilities for fiscal 2025 was $10.36M, a 1170.80% increase from fiscal 2024.
- Standard BioTools Inc. increase (decrease) in accrued liabilities for fiscal 2024 was $815.00K, a 86.82% decline from fiscal 2023.
- Standard BioTools Inc. increase (decrease) in accrued liabilities for fiscal 2023 was $6.18M, a 50.33% increase from fiscal 2022.
- Standard BioTools Inc. increase (decrease) in accrued liabilities for fiscal 2022 was $4.11M.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$14.14M 10-Q · filed 2026-08-05 | -$14.04M derived: sum of 3 quarters · filed 2026-08-05 | -$5.27M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$20.79M 10-Q · filed 2026-05-06 | -$20.69M derived: sum of 2 quarters · filed 2026-05-06 | -$11.91M derived: sum of 3 quarters · filed 2026-05-06 | -$2.67M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $98.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $8.87M derived: sum of 2 quarters · filed 2026-03-16 | $18.11M derived: sum of 3 quarters · filed 2026-08-05 | $10.36M 10-K · filed 2026-03-16 |
| 2025-09-30 | $8.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $18.01M derived: sum of 2 quarters · filed 2026-08-05 | $10.26M 10-Q · filed 2025-11-04 | $7.62M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $9.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.49M 10-Q · filed 2026-08-05 | -$1.15M derived: sum of 3 quarters · filed 2026-08-05 | -$1.56M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$7.75M 10-Q · filed 2026-05-06 | -$10.39M derived: sum of 2 quarters · filed 2026-05-06 | -$10.80M derived: sum of 3 quarters · filed 2026-05-06 | -$9.43M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$2.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$3.04M derived: sum of 2 quarters · filed 2026-03-16 | -$1.68M derived: sum of 3 quarters · filed 2026-03-16 | $815.00K 10-K · filed 2026-03-16 |
| 2024-09-30 | -$410.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $954.00K derived: sum of 2 quarters · filed 2025-11-04 | $3.45M 10-Q · filed 2025-11-04 | $4.18M derived: sum of 4 quarters · filed 2026-03-16 |
| 2024-06-30 | $1.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-15 | $3.86M 10-Q · filed 2025-08-15 | $4.59M derived: sum of 3 quarters · filed 2026-03-16 | $9.38M derived: sum of 4 quarters · filed 2026-03-16 |
| 2024-03-31 | $2.50M 10-Q · filed 2025-05-06 | $3.23M derived: sum of 2 quarters · filed 2026-03-16 | $8.02M derived: sum of 3 quarters · filed 2026-03-16 | $9.43M derived: sum of 4 quarters · filed 2026-03-16 |
| 2023-12-31 | $735.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $5.52M derived: sum of 2 quarters · filed 2026-03-16 | $6.94M derived: sum of 3 quarters · filed 2026-03-16 | $6.18M 10-K · filed 2026-03-16 |
| 2023-09-30 | $4.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $6.20M derived: sum of 2 quarters · filed 2024-11-06 | $5.45M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $1.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $659.00K 10-Q · filed 2024-08-06 | ||
| 2023-03-31 | -$754.00K 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | $4.11M 10-K · filed 2025-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |